PL3368046T3 - Syntetyczna kompozycja i sposób modulowania funkcji mózgu i zachowania - Google Patents

Syntetyczna kompozycja i sposób modulowania funkcji mózgu i zachowania

Info

Publication number
PL3368046T3
PL3368046T3 PL16859111.3T PL16859111T PL3368046T3 PL 3368046 T3 PL3368046 T3 PL 3368046T3 PL 16859111 T PL16859111 T PL 16859111T PL 3368046 T3 PL3368046 T3 PL 3368046T3
Authority
PL
Poland
Prior art keywords
behaviour
brain function
synthetic composition
modulating brain
modulating
Prior art date
Application number
PL16859111.3T
Other languages
English (en)
Inventor
Bruce Mcconnell
Emma ELISON
Louise Kristine VIGSNÆS
Original Assignee
Glycom A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glycom A/S filed Critical Glycom A/S
Publication of PL3368046T3 publication Critical patent/PL3368046T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15—Vitamins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H3/00—Compounds containing only hydrogen atoms and saccharide radicals having only carbon, hydrogen, and oxygen atoms
    • C07H3/06—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Nutrition Science (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PL16859111.3T 2015-10-28 2016-10-28 Syntetyczna kompozycja i sposób modulowania funkcji mózgu i zachowania PL3368046T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA201570696 2015-10-28
DKPA201670100 2016-02-24
PCT/DK2016/050344 WO2017071715A1 (en) 2015-10-28 2016-10-28 Synthetic composition and method for modulating brain function and behaviour

Publications (1)

Publication Number Publication Date
PL3368046T3 true PL3368046T3 (pl) 2022-11-28

Family

ID=58629784

Family Applications (1)

Application Number Title Priority Date Filing Date
PL16859111.3T PL3368046T3 (pl) 2015-10-28 2016-10-28 Syntetyczna kompozycja i sposób modulowania funkcji mózgu i zachowania

Country Status (7)

Country Link
US (2) US10835545B2 (pl)
EP (1) EP3368046B1 (pl)
CN (1) CN108348535B (pl)
DK (1) DK3368046T3 (pl)
ES (1) ES2927009T3 (pl)
PL (1) PL3368046T3 (pl)
WO (1) WO2017071715A1 (pl)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017190755A1 (en) * 2016-05-05 2017-11-09 Glycom A/S Composition comprising hmos for use in the treatment of mast cell mediated visceral hypersensitivity and/or pain
WO2017198276A1 (en) 2016-05-19 2017-11-23 Glycom A/S Synthetic composition
WO2018207110A1 (en) * 2017-05-09 2018-11-15 Glycom A/S Synthetic composition for microbiota modulation
WO2018215960A1 (en) * 2017-05-24 2018-11-29 Glycom A/S Synthetic composition comprising one or more human milk oligosaccharides (hmos)
US11541069B2 (en) 2017-11-02 2023-01-03 Glycom A/S One or more HMOs for reducing or preventing fatigue and/or improving focus or concentration
KR20190130720A (ko) * 2018-05-15 2019-11-25 (주)에이피테크놀로지 2'-푸코실락토오스를 포함하는 뇌졸중 예방용 조성물
PL3897902T3 (pl) * 2018-12-19 2024-02-26 Glycom A/S Rozdzielanie oligosacharydów
WO2021105943A1 (en) * 2019-11-27 2021-06-03 Glycom A/S MIXTURE OF HMOs
EP4072319A1 (en) * 2019-12-11 2022-10-19 Société des Produits Nestlé S.A. Compositions for use in the reduction of nociception and other health benefits in infants and young children
CA3164483A1 (en) * 2019-12-19 2021-06-24 Hill's Pet Nutrition, Inc. Compositions and methods of treating and reducing risk of conditions associated with elevated 4-ethylphenyl sulfate
US20240024343A1 (en) * 2020-12-04 2024-01-25 Glycom A/S Human milk oligosaccharides for use in supporting maturation or improvement of sleeping patterns
US20250360151A1 (en) 2022-06-09 2025-11-27 Societe Des Produits Nestle S.A. Nutritional composition comprising gos and hmos

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2796082B1 (fr) 1999-07-07 2003-06-27 Centre Nat Rech Scient Procede de production d'oligosaccharides
PT1991690E (pt) 2006-03-09 2014-04-22 Centre Nat Rech Scient Método para a produção de oligossacáridos sialilados
CA2758097A1 (en) 2009-04-07 2010-10-14 Glycom A/S Synthesis of 2'-o-fucosyllactose
EP2451462B1 (en) * 2009-07-06 2017-09-06 Children's Hospital Medical Center Inhibiting inflammation with milk oligosaccharides
TR201807143T4 (tr) * 2009-08-25 2018-06-21 Nestec Sa Bifidobacterium longum ve fonksiyonel gastrointestinal bozukluklar.
CN105330705A (zh) 2010-02-19 2016-02-17 格礼卡姆股份公司 用于制备含n-乙酰乳糖胺的四糖乳糖-n-新四糖(lnnt)的方法
CN103108956A (zh) 2010-07-16 2013-05-15 格力康公司 新型唾液酸寡糖衍生物的合成
AU2011351419A1 (en) 2010-12-29 2013-07-18 Nestec S.A. A nutritional composition comprising fiber and probiotics for reducing stress-related intestinal symptoms
US11337990B2 (en) 2010-12-31 2022-05-24 Abbott Laboratories Human milk oligosaccharides to promote growth of beneficial bacteria
PH12013501501A1 (en) 2011-02-10 2019-10-07 Nestec Sa Modulation of growth of bifidobacteria using a combination of oligosaccharides found in human milk
WO2012113404A1 (en) 2011-02-21 2012-08-30 Glycom A/S Novel glycosyl phosphites
CA2830025A1 (en) 2011-03-18 2012-09-27 Glycom A/S Synthesis of new fucose-containing carbohydrate derivatives
US20140323705A1 (en) 2011-05-13 2014-10-30 Markus Hederos Manufacture of lacto-n-tetraose
RU2013155453A (ru) 2011-05-13 2015-06-20 Глюком А/С Диверсификация молочных олигосахаридов человека (hmos) или их предшественников
JP2014513985A (ja) 2011-05-13 2014-06-19 グリコム アー／エス 人乳オリゴ糖（ｈｍｏ）又はその前駆体の形成方法
CA2846603A1 (en) 2011-08-29 2013-03-07 Abbott Laboratories Human milk oligosaccharides for preventing injury and/or promoting healing of the gastrointestinal tract
US20140235850A1 (en) 2011-09-30 2014-08-21 Glycom A/S Synthesis of hmo core structures
WO2013091660A1 (en) 2011-12-23 2013-06-27 Glycom A/S A method for obtaining crystalline lacto-n-tetraose and lacto-n-neotetraose precursors and mixtures thereof
WO2013139344A1 (en) 2012-03-20 2013-09-26 Glycom A/S Synthesis of the trisaccharide 3-o-fucosyllactose and intermediates thereof
JP2015512936A (ja) 2012-04-13 2015-04-30 トラスティーズ オブ ボストン カレッジ プレバイオティクス組成物およびその使用方法
JPWO2013161820A1 (ja) 2012-04-23 2015-12-24 国立大学法人京都大学 ビフィズス菌の増殖促進用組成物
DK2708145T3 (en) 2012-09-14 2016-07-18 Abbott Lab Nutritional Compositions for Use in Methods to Modulate Corticosterone Levels in Psychologically Stressed Individuals
EP2708147B1 (en) * 2012-09-14 2020-03-11 Abbott Laboratories Methods for increasing brain functionality using 2-fucosyl-lactose
CN104955344A (zh) 2012-12-18 2015-09-30 雅培制药有限公司 包含神经保护膳食寡糖的营养组合物
CN104822279B (zh) * 2012-12-18 2020-09-11 雅培制药有限公司 缓减应激症状的人乳寡糖
RU2015143177A (ru) 2013-03-12 2017-04-18 Нестек С.А. Анализы и способы выбора схемы лечения для субъекта с депрессией
HK1231398A1 (zh) 2014-04-08 2017-12-22 Abbott Laboratories 使用人乳寡糖增强对病原体的粘膜先天免疫反应和/或检测的方法
US20150305384A1 (en) 2014-04-25 2015-10-29 Mead Johnson Nutrition Company Pediatric nutritional composition with human milk oligosaccahrides, prebiotics and probiotics
US11040050B2 (en) * 2014-10-29 2021-06-22 Glycom A/S Composition comprising HMSs/HMOs and use thereof
US11040049B2 (en) * 2014-10-29 2021-06-22 Glycom A/S Composition comprising HMSs/HMOs and use thereof
US20160243139A1 (en) 2014-10-29 2016-08-25 Glycom A/S Composition comprising HMSs/HMOs and use thereof
EP3212197A4 (en) * 2014-10-29 2018-07-11 Glycom A/S Synthetic composition and method for treating irritable bowel syndrome
US20160287637A1 (en) 2014-12-08 2016-10-06 Glycom A/S Synthetic composition and method for modulating emotion and mood disorders
WO2017071716A1 (en) 2015-10-28 2017-05-04 Glycom A/S Synthetic composition and method for modulating emotion and mood disorders
WO2017144062A1 (en) * 2016-02-24 2017-08-31 Glycom A/S Synthetic composition for microbiota modulation
WO2017198276A1 (en) * 2016-05-19 2017-11-23 Glycom A/S Synthetic composition
EP3589139A4 (en) * 2017-03-01 2020-12-23 Glycom A/S SYNTHETIC COMPOSITION FOR MICROBIOTE MODULATION
CN111556755A (zh) * 2017-12-05 2020-08-18 格礼卡姆股份公司 用于治疗偏头痛的人乳寡糖

Also Published As

Publication number Publication date
EP3368046A1 (en) 2018-09-05
US20210077513A1 (en) 2021-03-18
DK3368046T3 (da) 2022-10-31
CN108348535A (zh) 2018-07-31
ES2927009T3 (es) 2022-10-31
US20180369260A1 (en) 2018-12-27
US11684630B2 (en) 2023-06-27
CN108348535B (zh) 2021-08-31
EP3368046B1 (en) 2022-07-27
US10835545B2 (en) 2020-11-17
EP3368046A4 (en) 2019-07-03
WO2017071715A1 (en) 2017-05-04

Similar Documents

Publication Publication Date Title
IL286669A (en) Compounds and methods for modulating tmprss6 expression
PL3368046T3 (pl) Syntetyczna kompozycja i sposób modulowania funkcji mózgu i zachowania
IL285229A (en) Compounds and methods for modulating RNA function
IL271659A (en) Compositions and methods for modulating expression of complement factor B
ZA201801600B (en) Compounds and methods for modulating angiotensinogen expression
IL254780B (en) Electro-optical modulator
EP3380000A4 (en) METHOD AND DEVICE FOR SUPPLYING THE BRAIN WITH IRRITATION
IL247389A0 (en) Methods and preparations for personal pain management
GB201512283D0 (en) Track behaviour events
HUE042875T2 (hu) Rendszerek és eljárások modulációs és kódolási séma választásra és konfigurálásra
PT3353303T (pt) Composições e métodos para modulação da expressão de ataxina 3
GB201504222D0 (en) Droplet assemblies and methods for producing droplet assemblies
GB201520255D0 (en) Composition and method
GB201611699D0 (en) Behaviour modification
IL254197A0 (en) Methods to modulate bone density
SG11201705265RA (en) Composition for forming underlayer and method for forming underlayer therewith
GB201509420D0 (en) Composition and method
GB201401612D0 (en) Synthetic method
PL3650431T3 (pl) Kompozycja zawierająca C<sub>8</sub>F<sub>17</sub>Br i sposób wytwarzania C<sub>8</sub>F<sub>17</sub>Br
GB201513492D0 (en) Method and composition
ZA201803467B (en) Management method
SMT202100435T1 (it) Metodo di trattamento cosmetico
GB201712304D0 (en) Synthetic methods
GB201621716D0 (en) Composition and method for bone regeneration
AU2015902928A0 (en) New synthetic methods